Breaking News

Ajinomoto Althea Expands Fill/Finish Mfg. Capacity

March 16, 2016

Adds second shift and operational capabilities

Ajinomoto Althea, Inc. is expanding capacity with the addition of a second manufacturing shift to support sterile fill and finish parenteral manufacturing operations for clinical and commercial drug programs. The second shift will come on-line in early June, increasing the number of manufacturing slots for drug programs, reducing lead times from project kickoff to fill date.

To support this increase in parenteral manufacturing capacity, Althea has invested in additional operational capabilities, more visual inspection suites, automated quality systems, and project management expansion. The expansion also accomodates its microbial and plasmid DNA capabilities, crystallization formulation technology (Crystalomics) programs, and its recent entry into the highly potent API and ADC bioconjugation and fill and finish services.
 
Chris Duffy, senior vice president of operations, said, “We are very pleased and eager to provide this additional fill and finish capacity to all of our clients. We recognize and appreciate the need for shorter lead times and flexible timelines, which are critical to developers of biologics-based drug products. The addition of this second manufacturing shift will allow us to further accommodate the substantial increase in demand we’ve observed from our clinical and commercial partners.”
 
 
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision